IMMP - Dosing gets underway in Immutep eftilagimod alpha lung carcinoma trial

Immutep (NASDAQ:IMMP) announces that the first patient has been dosed in the investigator-initiated trial for the triple combination including eftilagimod alpha for the treatment of metastatic non-small cell lung carcinoma. The patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immutep’s lead product candidate eftilagimod alpha (efti or IMP321). The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022. Patients will receive 30 mg subcutaneous doses of efti every two weeks in conjunction with standard of care chemotherapy plus anti-PD-1 therapy. The trial will assess the safety, tolerability and initial efficacy of the combination.

For further details see:

Dosing gets underway in Immutep eftilagimod alpha lung carcinoma trial